Hyloris Closes A Dramatic 2024 With A Move Towards Profit

The Firm Reported Increased Revenue Driven By Royalties

After announcing updates in its ongoing legal battle and a leadership shakeup earlier this fiscal year, Hyloris closed 2024 with a slight rise in revenue and a shrinking of its reported net loss.

Belgium map and flag
Belgium updates rules on importing unlicensed products

Hyloris Pharmaceuticals has reported a slight rise in its total revenue as part of its full year results for 2024, marking a close to a particularly tumultuous period for the Belgian value-added medicines specialist that has moved closer to profit.

For the whole of the 2024 financial year, Hyloris reported growth in its total revenue and other operating income to...

More from Generics Bulletin

More from Business